Recent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the vital body organs.
Potential participants with a sarcoma diagnosis will be referred to Radiation Oncology during this study. If the participant is interested in participating in this study, s/he receives radiation treatment daily for 5 consecutive days except for weekends and holidays. Within 12 weeks of completing the radiation therapy, the participant will have the primary tumor surgically removed. The radiation oncology team will follow the patients for 5 years after completing radiation therapy.
Histologically confirmed sarcoma
Primary or recurrent disease involving the abdomen or pelvis
Resectable primary lesion
Age ≥ 12 years old
Active treatment of a separate malignancy
History of prior irradiation to the area targeted for treatment
Single group
Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy
Radiationstereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
Radiation morbidity at 2 years
Evaluate the 2 year rate of grade ≥2 radiation morbidity, according to Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.
Local Control
Defined as freedom from radiographic progression of the treated site. It will be evaluated using CT and/or MRI of the abdomen and pelvis.
Regional Control
Defined as freedom from radiographic progression in the abdomen or pelvis outside of the treated site. It will be evaluated using CT and/or MRI of the abdomen and pelvis.
Distant metastasis
Progression free survival
Click on the lead sponsor to view all of their trials.
